Following FDA approval for its kidney drug treatment, shares of Travere Therapeutics (TVTX) popped. George Tsilis joins Market on Close to discuss the company's makeup and what might have caused the analysts at Guggenheim to upgrade the stock to a Buy rating.
Market On Close
09 Sep 2024
SHARE